Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Beam Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

About Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company specializing in precision genetic medicines through proprietary base editing technology, which enables precise, efficient single-base genome modifications without double-stranded DNA breaks. Its platform integrates gene editing, delivery modalities, and manufacturing to develop therapies for genetic and hematological diseases, targeting markets with high unmet medical needs. Beam’s business model combines internal development with strategic collaborations to advance and commercialize innovative gene editing treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Beam Therapeutics Inc.

1
1
Beam Therapeutics Inc. Beam Therapeutics Reports $31.7M Revenue Growth and $94.3M Net Loss for Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Beam Therapeutics Inc. Beam Therapeutics Reports $79.99M Net Loss and $139.74M Revenue for 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Beam Therapeutics Inc. Beam Therapeutics Reports $112.7 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Beam Therapeutics Inc. Beam Therapeutics Reports $102.3 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Beam Therapeutics Inc. Beam Therapeutics Reports $109.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Beam Therapeutics Inc. Beam Therapeutics Reports Decline in Revenue and Net Loss, Despite Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments